Oem Channel was Anika Therapeutics’s largest product and service line in fiscal 2025, bringing in $64.41M of $112.82M (57%).
| Product and Service | FY 2010 | FY 2011 | FY 2016 | FY 2017 | FY 2017 | FY 2017 | FY 2017 | FY 2018 | FY 2018 | FY 2018 | FY 2018 | FY 2019 | FY 2019 | FY 2019 | FY 2019 | FY 2020 | FY 2021 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Joint Pain Management Therapies | — | — | — | |||||||||||||||||
| Oa Pain Management | — | — | — | |||||||||||||||||
| Orthobiologics | — | — | — | |||||||||||||||||
| Oem Channel | $84.65M | $77.77M | $64.41M | |||||||||||||||||
| Commercial Channel | $36.15M | $42.14M | $48.41M | |||||||||||||||||
| Product | — | — | — | |||||||||||||||||
| Joint Preservation & Restoration | — | — | — | |||||||||||||||||
| Ophthalmic | — | — | — | |||||||||||||||||
| Non-Orthopedic | — | — | — | |||||||||||||||||
| Surgical | — | — | — | |||||||||||||||||
| Manufactured Product, Other | — | — | — | |||||||||||||||||
| Other | — | — | — | |||||||||||||||||
| Dermal | — | — | — | |||||||||||||||||
| Veterinary | — | — | — | |||||||||||||||||
| Service | — | — | — | |||||||||||||||||
| Licensing, Milestone & Contract Revenue | — | — | — | |||||||||||||||||
| Total | $120.79M | $119.91M | $112.82M |
Anika Therapeutics brought in $112.82M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That was down 5.9% from $119.91M in fiscal 2024. Oem Channel was the largest at $64.41M (57.1%), ahead of Commercial Channel at $48.41M (42.9%).
Compared with fiscal 2024, Commercial Channel grew 14.9% to $48.41M, while Oem Channel fell 17.2% to $64.41M. From fiscal 2023 to 2025, combined revenue from these lines fell from $120.79M to $112.82M, a compound annual decline of 3.4%. Oem Channel's share of the total fell from 70.1% to 57.1%.
United States was Anika Therapeutics’s largest region in fiscal 2025, bringing in $70.06M of $112.82M (62%).
| Geography | FY 2012 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| United States | $86.91M | $82.45M | $70.06M | |||||||
| Europe | $17.31M | $19.40M | $22.21M | |||||||
| Other Location | $16.57M | $18.06M | $20.55M | |||||||
| Total | $120.79M | $119.91M | $112.82M |
Anika Therapeutics brought in $112.82M from its three regions in fiscal 2025, the year ended December 31, 2025. That was down 5.9% from $119.91M in fiscal 2024. United States was the largest at $70.06M (62.1%), ahead of Europe at $22.21M (19.7%) and Other Location at $20.55M (18.2%).
Compared with fiscal 2024, Europe grew fastest, up 14.5% to $22.21M, while United States fell the most, down 15.0% to $70.06M. From fiscal 2023 to 2025, combined revenue from these regions fell from $120.79M to $112.82M, a compound annual decline of 3.4%. United States' share of the total fell from 72.0% to 62.1%.
Anika Therapeutics (ANIK) reports its revenue by product and service and by geography. In fiscal 2025, Oem Channel was its largest product and service line, bringing in $64.41M (57.1% of the total), followed by Commercial Channel at $48.41M (42.9%).
Oem Channel was Anika Therapeutics' largest product and service line in fiscal 2025, bringing in $64.41M, or 57.1% of the $112.82M total across its two product and service lines.
United States was Anika Therapeutics' largest region in fiscal 2025, bringing in $70.06M, or 62.1% of the $112.82M total across its three regions.
Commercial Channel grew faster than Oem Channel in fiscal 2025, up 14.9% from $42.14M to $48.41M. Oem Channel fell 17.2% to $64.41M.
Every figure comes from Anika Therapeutics' annual financial filings, as reported. Each line keeps the name Anika Therapeutics gives it, and years follow its fiscal calendar.
Anika Therapeutics' revenue by product and service goes back to fiscal 2010, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.